Narcolepsy: Selective hypocretin (orexin) neuronal loss and multiple signaling deficiencies

Neurology

Volumn 65, Issue 8, 2005, Pages 1152-1153

  Bassetti, Claudio L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN; OREXIN; PENTRAXIN;

CATAPLEXY; EDITORIAL; HYPOTHALAMUS; NARCOLEPSY; NONREM SLEEP; PRIORITY JOURNAL; REM SLEEP; WAKEFULNESS;

EID: 27144553443     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000186118.96509.94     Document Type: Editorial

References (17)

1. Sturzenegger C, Bassetti C. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004;13:395-406.
2. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005;46:787-798.
3. Lin L, Faraco J, Li R, et al. The sleep disorder of canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-376.
4. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-451.
5. Nishino N, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40.
6. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997.
7. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474.
8. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-1562.
9. Blouin AM, Thannickal TC, Worley PF, Baraban JM, Reti IM, Siegel JM. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 2005;65:1189-1192.
10. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005;65:1184-1188.
11. Smith AJ, Jackson MW, Neufing P, McEvoy RD, Gordon TP. A functional autoantibody in narcolepsy. Lancet 2004;364:2122-2124.
12. Lecendraux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12:347-348.
13. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56:905-908.
14. Baumann C, Khatami R, Werth E, Bassetti C. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy. J Neurol Neurosurg Psychiatry 2005 (in press).
15. Khatami R, Maret S, Werth E, Rétey J, Schmid D, Maly F, et al. A monozygotic twin pair concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. Lancet 2004;363:1199-1200.
16. Baumann CR, Stocker R, Imhof HG, Trentz O, Hersberger M, Bassetti C. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 2005;65:147-149.
17. Nikoshkov A, Hurd YL, Yakovleva T, et al. Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain. FASEB 2005 (in press).